Clinical Trial Update: Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the combination of iadademstat and gilteritinib in patients with relapsed/refractory acute myeloid leukemia with FLT3 mutation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Gilteritinib (gilteritinib)
• Iadademstat (iadademstat)

Snippet

Sponsor: Oryzon Genomics S.A. | Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Status: RECRUITING